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In critically ill patients, any acute organ injury is
associated with a sudden change of circulating factors
that may play a role in distant organ dysfunction
through a complex cross-talk. In this issue, Virzì and
colleagues discuss the relevance of humoral signalling
between heart and kidney, focusing on type 1 and
type 3 cardio-renal syndrome. We herein review the
mechanisms of heart-kidney cross-talk, discussing the
role of circulating detrimental mediators in the
pathogenetic mechanisms of cardio-renal syndrome.thetic innervations that regulate blood pressure, vascularThe ‘humoral theory’ proposed by the greek physician
Hippocrates sustained that the body is composed of the
four basic humors, black bile, yellow bile, phlegm and
blood. According to this theory, an excess or a deficit of
one of these humors leads to a disease state. Nowadays,
the role of an imbalance of humoral mediators in differ-
ent diseases is still present, particularly in the field of
multiple organ failure in critical illness. In this issue,
Virzì and colleagues demonstrate the relevance of
humoral signalling in type 1 and type 3 cardio-renal syn-
drome (CRS) [1].
Kidney seems to play a key role in the interplay be-
tween distant organs: acute kidney injury (AKI) usually
develops as a result of the presence of hypoperfusion or
a systemic inflammatory reaction caused by a primary
injury in the lung, brain, liver or heart [2]. AKI contrib-
utes to the development of this deleterious cross-talk
through deregulation of the immune system. This effect
may be ascribed to the loss of function of tubular cells
that are immunologically active operating as antigen-* Correspondence: vincenzo.cantaluppi@unito.it
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ance of inflammatory mediators [3,4].
Distant organs continuously communicate through a
complex network of extracellular molecules. CRS is de-
fined as a primary disorder of heart or kidney whereby
acute or chronic dysfunction originating from one organ
may induce acute or chronic dysfunction of another [5].
Type 1 CRS reflects an abrupt worsening of cardiac
function that consequently leads to AKI. Type 2 CRS in-
cludes chronic abnormalities of cardiac function able to
induce progressive chronic kidney disease. Heart and
kidney are both supplied by sympathetic and parasympa-
tone, diuresis, natriuresis and tissue oxygenation. In type
1 and type 2 CRS, the renin-angiotensin-aldosterone sys-
tem (RAAS) plays a pivotal role in the modulation of
renal perfusion pressure and RAAS activation is associ-
ated with vasoconstriction mediated by enhanced release
of endothelin [6]. In type 2 CRS, RAAS activation in-
duces oxidative stress and release of free oxygen radicals,
thus favouring apoptosis and fibrosis with progression of
both renal and cardiac dysfunction [7].
Type 3 CRS consists of an acute cardiac dysfunction
following AKI: the pathogenetic mechanisms of cardio-
myocyte injury after ischemic AKI can be ascribed to
apoptosis associated with increased plasma levels of
TNF-alpha. Indeed, the selective blockade of TNF-alpha
limited cardiac apoptosis [8]. To further support the
relevance of humoral signalling in type 3 CRS, Naito
and colleagues [9] elegantly demonstrated that AKI sen-
sitizes the kidney to endotoxin-driven production of cy-
tokines and chemokines. This hyper-responsiveness to
endotoxin is likely mediated by an increase of histone
methylation and consequent recruitment of RNA poly-
merase II to the TNF-alpha and MCP-1 genes.
In type 4 CRS, the accumulation of water soluble and
protein-bound uremic toxins contributes to the typical
endothelial dysfunction and vascular calcification of
chronic kidney disease patients [10]. The endogenous
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and indoxyl-sulphate induce oxidative stress, and endothe-
lial and cardiomyocyte apoptosis [10,11]. Elevated plasma
levels of these uremic toxins are associated with increased
cardiovascular risk and mortality [12].
Type 5 CRS reflects a systemic condition causing simul-
taneous cardiac and renal dysfunction. Sepsis, the systemic
response to infection, is the main cause of type 5 CRS.
The mechanisms of cardiac and renal dysfunction during
sepsis are related to the detrimental role of circulating me-
diators such as bacterial compounds (lipopolysaccharide
and inflammatory cytokines (TNF-alpha, interleukin-6))
able to induce apoptotic tissue damage [13].
In CRS, other metabolites, nucleic acids and lipids can
be released by different types of activated cells and circu-
late into the bloodstream free or bound to specific carriers
such as extracellular vesicles (EVs). EVs are membrane-
delimited vesicles released from the plasma membrane of
different cell types and able to transfer proteins, bioactive
lipids and genetic information to a target cell [14].
Platelet-derived EVs isolated from plasma of septic pa-
tients induce myocardial and endothelial dysfunction
through activation of caspase-3 and generation of super-
oxide, nitric oxide and peroxynitrite [15].
In conclusion, humoral signalling plays a key role in
the pathogenesis of heart and kidney injury in CRS. The
blockade of this detrimental humoral cross-talk may lead
to an improvement of organ failure. This could be ob-
tained by using early biomarkers of disease or by devel-
oping new therapeutic approaches aimed to limit the
inflammatory response, including blood purification
techniques and stem cell-based treatments.
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